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Abstract
Purpose: The present study aimed to explore the safety profile and clinical efficacy of CT-guided radioactive seed
implantation in treating local recurrent rectal carcinoma.
Materials and methods: CT-guided
125I seed implantation was carried out in 20 patients with locally recurrent
rectal carcinoma. 14 of the 20 patient had prior adjuvant external-beam radiation therapy (EBRT). The treatment
planning system (TPS) was used preoperatively to reconstruct three dimensional images of the tumor and to
calculate the estimated seed number and distribution. The median matched peripheral dose (MPD) was 120 Gy
(range, 100-160 Gy).
Results: Of the 20 patients, 12 were male, 8 were female, and ages ranged from 38 to 78, with a median age of
62. Duration of follow-up was 3-34 months. The response rate of pain relief was 85% (17/20). Repeat CT scan 2
months following the procedure revealed complete response (CR) of the tumor in 2 patients, partial response (PR)
in 13 patients, stable disease (SD) in 3 patients, and progressive disease (PD) in 2 patients. 75% of patients had
either CR or PR. Median survival time was 18.8 months (95% CI: 3.5-22.4 months). 1 and 2 year survival rates were
75% and 25%, respectively. 4 patients died of recurrent tumor; 4 patients died of distant metastases; 9 patients
died of recurrent tumor and distant metastases. 3 patients survived after 2 year follow up. Two patients were
found to have mild hematochezia, which was reversible with symptomatic management.
Conclusion: CT-guided
125I seed implantation appeared to be a safe, useful and less complicated interventional
treatment option for local recurrent rectal carcinoma.
Introduction
Post-operative chemotherapy and external-beam radia-
tion therapy (EBRT) is the standard adjuvant treatment
for high-risk resected rectal carcinoma [1]. Despite the
effectiveness of combined adjuvant therapies, local
recurrence remains a significant problem in the 10-15%
of high-risk patients who subsequently experience local
relapse [2,3]. Successful surgical salvage of pelvic
relapses is restricted to anastomotic recurrences and
some centrally located relapses. In fact, more than 3 of
4 locally recurrent tumors cannot be resected
completely [4,5]. Palliative surgical resection without
additional therapy has resulted in a 3-yr survival of 8%
with no 5-yr survivors in a recent Mayo Clinic series
[6]. Interstitial implantation of
125I seeds into the tumor
delivers a high dose of radiation to the tumor (range
140-180 Gy) by a very sharp fall-off containing the
implanted volume, thus sparing nearby normal tissues.
In addition,
125I seed has a slow continuous release of
radiation (initial dose rate 0.07-0.09 Gy/h) that is radio-
biologically advantageous, allowing repair of sublethal
damage and reoxygenation of hypoxic areas in the late-
responding tissues [7]. Therefore, radioactive
125Is e e d
implantation is another choice for treatment of malig-
nant tumors, which is widely applied for its curative
effect, minimal surgical trauma, and few complications
[8-15]. At our institution, we utilize
125I seed replace-
ment routinely in recurrent tumors in various sites,
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chytherapy is also feasible for rectal lesions. Therefore,
we report here the results for 20 locally recurrent rectal
cancer patients following
125I seed implantation.
Materials and methods
Patients
This retrospective study was approved by the hospital
ethics committee, and all patients provided written
informed consent. Between October 2006 and August
2009, 20 consecutive patients with locally recurrent rec-
tal carcinoma (12 men and 8 women, mean age 63.5
years) were included in this retrospective, nonrando-
mized study. Of these patients, 3 had a tumor in the
rectal upper third, 4 had a tumor in the rectal middle
third, and 13 had a tumor in the rectal lower third.
Median diameter of the tumor was 4.1 cm. All patients
had undergone prior surgeries. Of the 20 patients, 10
had had both prior adjuvant external-beam radiation
therapy (EBRT) and chemotherapy, 4 had received
EBRT alone, and 2 had undergone adjuvant chemother-
apy alone. The other 4 patients could not tolerate or
refuse to have EBRT or adjuvant chemotherapy. The
median EBRT dose applied in the adjuvant setting was
60 Gy (range 50-70 Gy). Patient characteristics are listed
in Table 1. Patients were first diagnosed by using com-
puted tomography (CT) or magnetic resonance imaging
(MRI). Histological confirmation of the diagnosis was
achieved in all 20 cases by CT-guided fine needle aspira-
tion (FNA) 1 week before implantation. FNA has been
accepted as a gold standard in the diagnosis of tumor
cytology [16-20]. Furthermore, 9 patients had elevated
serum carcinoembryonic antigen (CEA) level.
Instruments
We used a Siemens CT scanner with pelvic imaging
conditions of 120 kV, 275 mA, and width of 5 mm.
Dose distribution was calculated using a Fudan TPS2.00
brachytherapy planning system (Fudan University,
Shanghai, China) based on the American Association of
Physicists in Medicine TG43 brachytherapy formalism
[21]. A series CT images are entered to reconstruct the
three-dimensional graph of tumor; tumor volume is cal-
culated and the three-dimensional graphs are displayed
by the system. Figure 1 showed the distributions of
125I
seeds and isodose curves after seed implantation from
CT scan, which was analyzed by Fudan TPS 2.00. The
125I sealed seed sources were supplied by XinKe Phar-
maceutical Ltd, Shanghai. For the
125I seed implantation
we used 18G implantation needles and a turntable
implantation gun (XinKe Pharmaceutical Ltd, Shanghai,
China). The
125I seeds were manufactured from silver
rods, which absorb
125I, and were enclosed in a titanium
capsule welded by laser (XinKe Pharmaceutical Ltd,
Shanghai, China). The diameter of each seed was 0.8
mm, the length was 4.5 mm, and thickness of the wall
of the titanium capsule was 0.05 mm.
125Ip r o d u c e s
gamma rays (5% of 35 keV, 95% of 28 keV) with a half-
life of 59.6 days, half-value thickness of 0.025 mm of
lead, penetration of 17 mm, incipient rate of 7 cGy/h,
and activities of 0.6-0.8 mCi.
CT-guided implantation protocol
One week prior to seeds implantation, all patients
underwent a detailed tumor volume study using CT
scans with the thickness of 5 mm. The radiation oncolo-
gist outlined the gross tumor volume (GTV) and areas
at risk for subclinical disease on each transverse image.
The planning target volume (PTV) included the entire
GTV and 0.5-1.0 cm margins. The dose was prescribed
as the minimal peripheral dose (MPD) encompassing
the PTV. The median MPD was 120 Gy (range 100-160
Table 1 Patient characteristics
Characteristic n %
Number of patients 20 100
Median age (range) 63.5(41-87)
Gender
Male 12 60
Female 8 40
Pathology
Adenocarcinoma 18 90
Undifferentiated carcinoma 1 5
Malignant hemangiopericytoma 1 5
Tumor stage
T2N0M 6 30
T2N1M0 2 10
T3N1M0 9 45
T3N2M0 2 10
T4N0M0 1 5
Tumor site
Upper third 3 15
Middle third 4 20
Lower third 13 65
Location
Presacral region 7 35
Anastomotic junction without expansion to the
sacrum
13 65
Prior treatments
Surgery 20 100
Miles 13 65
Dixon 7 35
TME 0 0
Radiation therapy & chemotherapy 10 50
Chemotherapy alone 2 10
Radiation therapy alone 4 20
none 4 20
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125I seeds were calcu-
lated using computerized treatment planning system. To
reach the maximum radiation effect, the number of
seeds implanted was 15% more than needed. Implanta-
tion was guided by CT according to our TPS.
125Iw i t h
a nominal activity of 0.6-0.8 mCi/seed and a diameter of
less than 1 mm was used as a radiation source and
implanted into the recurrent rectal tumor under fluoro-
scopy CT guidance, at a spacing of 1 cm, avoiding punc-
turing vessels, urinary bladder, and other nearby
structures. Implant parameters are listed in Table 2.
Patients were placed on a clear liquid diet 24 hours
prior to the implantation. All the brachytherapy
implants were performed in a standard CT room under
local anesthesia. CT imaging was taken at intervals of 5
mm. The distance between the adjacent implantation
needles was approximately 1 cm. Repeat CT with the
implantation needles in place permitted adjustment of
depth and angle of needle direction. Two to five seeds
per needle were loaded, and seeds were released 0.5-1
cm apart upon withdrawing the needles. Patients were
kept in our radiooncology/interventional ward for 2 full
days.
Clinical benefit response (CBR)
Clinical benefit response was derived from measurement
of pain, functional impairment (assessed by KPS), and
weight loss [22]. For patients to achieve an overall rating
of positive CBR, they had to be positive for at least one
parameter (pain, performance, status, or weight) without
being negative for any of the others [23]. This improve-
ment had to last for at least 4 weeks. Visual analog scale
(VAS) pain score was recorded as level 0 to 10, in
which 0 indicated no pain, 1 to 3 indicated mild pain, 4
to 7 meant moderate pain, and 8 to 10 severe pain.
Scoring began after the
125I seeds were implanted.
Evaluation of curative effect
Patients were examined by CT 2 months after the
operation. The efficacy was determined according to the
tumor response standards suggested by the World
Health Organization [24]. Briefly, complete response
(CR) was defined as the complete disappearance of the
lesion lasting for more than 4 weeks. Partial response
(PR) referred to the situation where the size (i.e., the
longest dimension multiplied by maximal upright
dimension) of the lesion decreased by more than 50%
and then remained unchanged for 4 weeks. Stable dis-
ease (SD) was defined as the situation where the size of
the tumor decreased by less than 50% or increased by
less than 25%. Response rate was defined as the sum of
CR and PR. Local tumor control after brachytherapy
was defined as the absence of tumor progression in CT
(SD+PR+CR). Serum CEA level was checked every
month post-implantation as an indicator of prognosis.
Postimplant chemotherapy and radiation therapy
Three out of 20 patients who gave consent to che-
motherapy received combined treatment with Oxalipla-
tin 100 mg/m
2 and 5-fluorouracil (5-FU) 125 mg/m
2 1
week after implantation. The chemotherapy was a 2-day
schedule which contained Oxaliplatin on the first day
followed by 2 days of 5-FU. The chemotherapy was
repeated every 3 weeks for up to six cycles if tolerated.
Post-implantation EBRT was generally recommended
for previously unirradiated patients; however, no patient
received EBRT if they had post-operative complications
or were unable to receive the planned EBRT or refused
further therapy.
Follow-up
All 20 patients entered the follow-up phase immediately
after the implantation. The intended follow-up period
was 34 months, with first visits at 1 month post
Figure 1 A typical transverse slice showing the distributions of
125I seeds and isodose curves after seed implantation from CT
scan. The isodose lines shown are 300 Gy (brown), 160 Gy (red),
100 Gy (blue), 80 Gy (green) and 40 Gy (yellow). PTV and
125I seeds
are shown in light grey circle and blue dots, respectively.
Table 2 Implant parameters
Characteristic Median Range
Volume implanted (cm3) 68.9 26.9-97.3
MPD (Gy) 120 100-160
Dose rate (Gy/h) 0.07 0.05-0.09
Total activity (mCi) 18.2 9.5-66.6
No. seeds 58 19-111
Activity/seed (mCi) 0.7 0.6-0.8
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cal examination, blood sampling, and imaging studies,
including chest X-ray, abdominal and pelvic CT scans
and ultrasonography, performed earlier if a new clinical
sign or symptom appeared. No patients were lost to fol-
low-up. Follow-up pelvic CT scans to evaluate response
were obtained on all patients at various time intervals
from implantation.
Statistical analysis
With SPSS 13.0 software, quantitative indicators before
and after the operation were compared using paired t
test or nonparametric methods. The median survival
time of survival analysis was evaluated by the Wilcoxon
test and Kaplan-Meier methods. A P value of less than
0.05 was defined as statistically significant.
Results
Effects on cancer-associated Karnofsky and pain physical
score
Karnofsky score increased dramatically post-
125I implan-
tation as indicated in nutritional status, sleeping time,
and functional level (P < 0.05). Thus the overall quality
of life improved. Details are listed in Table 3.
Pain relief
Symptoms of refractory pain were significantly resolved
post-treatment (P < 0.05). In 20 patients, 11 (55.0%)
patients had severe pain; 5 (25.0%) patients had moder-
ate pain; 4 (20.0%) patients had mild pain before seeds
implant. The response rate of pain relief was 85%.
Change of pain score is shown in Table 4.
Response to treatment
Tumor response, which was demonstrated on repeated
CT film 3 months post-treatment, revealed complete
response (CR) in 2 cases, partial response (PR) in 13
cases (Figure 2), stable disease (SD) in 3 cases, and pro-
gressive disease (PD) in 2 cases. Overall responding rate
(CR+PR) for this group of patients was 75%. Local
tumor control rate was 90%. 1- and 2-year local control
rates were 65.0% and 15.0%, respectively (Figure 3). 4
cases died as a result of recurrent tumor progression; 4
cases died because of distant metastases; 9 cases died of
recurrent tumor progression and distant metastases. 3
cases survived to end of the follow-up. Elevated serum
CEA level before
125I seeds implantation were detected
in 9 cases, which reduced in 5 of 9, no change in 3 of 9,
and increased in 1 of 9 after 1-3 months.
Overall survival
Follow-up period was 3 to 34 months, the median time
was 22 months. 14 patients and 6 patients reached the
one-year and two-year follow-up, respectively. Median
survival time for all patients was 18.8 months (95% CI:
3.5-22.4 months). The estimated 1- and 2-year survival
rates were 75% and 25%, respectively (Figure 4).
Adverse reactions
There were no major complications such as fever, radia-
tion enteritis, colorectal tract perforation and detected
during our follow-up period. Two (10%) of twenty had
grade one lower gastrointestinal reaction. The patients
were found to have mild hematochezia, which was
reversible with symptomatic management. All patients
underwent an immediate post-procedure CT scan, no
125I seeds migrated to other tissues or organs. Bowel
and rectal complaints were documented using a modi-
fied Radiation Therapy Oncology Group (RTOG) rectal
symptom scoring scale [25].
Discussion
Various therapeutic modalities have been applied in the
treatment of local recurrent rectal cancer, such as sur-
gery, radiotherapy and chemotherapy - either alone or
in combination. A five-year disease-free survival rate of
less than 10 percent has been reported after radiation
therapy with or without chemotherapy, but radiation
therapy alone or combined with chemotherapy can pro-
vide temporary relief of symptoms [26,27]. In patients
who undergo radical surgery for rectal cancer, 4-33%
develop locoregional relapse. Without treatment, these
patients with local recurrent rectal cancer have a median
survival of 8 months [28-31]. In non-fixed recurrent
tumors, complete resection can be achieved with limited
surgery such as abdomino-perineal resection and the
outcomes are relatively favorable. 50 percent of patients
with recurrent cancer after curative surgery have an iso-
lated pelvic tumor which could be treated by salvage
surgery. However, the actual salvage surgery rate ranges
between 30 and 40 percent [32-34]. Our goals of treat-
ment for locally recurrent rectal cancer are palliation of
symptoms, better quality of life, and fewer treatment-
Table 3 Change of Karnofsky physical score
100 90 80 70 60
Pre-op 0 (0/20) 5.0 (1/20) 5.0 (1/20) 40.0(8/20) 50.0 (10/20)
Pre-op 0 (0/20) 55.0 (11/20) 25.0 (5/20) 15.0 (3/20) 5.0 (1/20)
Data are presented as % (cases)
Table 4 Change of pain score
No pain
(%)
Mild pain
(%)
Moderate pain
(%)
Severe pain
(%)
Pre-op 0 (0/20) 20.0 (4/20 25.0 (5/20) 55.0 (11/20)
Post-op 30.0 (6/20) 40.0 (8/20) 15.0 (3/20) 15.0 (3/20)
Data are presented as % (cases)
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active seeds might be an alternative in the treatment of
local recurrent rectal carcinoma.
Percutaneous image-guided seed implantation, which
can be performed without surgery or general anesthesia,
has attracted increasing attention because of its ability
to increase radiation dose to the region of interest with-
out damaging neighboring organs [35]. Many published
work [9-15] had reported percutaneous Iodine-125 seeds
implantation as a sole modality showed promising
results in the treatment of malignant tumor, such as
recurrent rectal carcinoma, non-small cell lung cancer,
recurrent soft tissue sarcomas, spinal metastatic and pri-
mary paraspinal malignancies, recurrent head and neck
cancers, and so on. With this technique, highly effective
radiation doses are applied as a single fraction, ensuring
protracted cell killing over a period of up to several
weeks or months.
Lefevre et al. [36] reported a series of 8 patients with
local recurrence of pelvic cancer treated with radiofre-
quency ablation (RFA), complications occurred in six
patients including minor pain, ureteric obstruction and
colo-vesical fistula. It allowed good symptom control in
patients with pain but morbidity was high. Ohhigashi et
al. [37,38] published a small series of 10 patients to eval-
uate RF ablation as new local treatment for recurrence
of rectal carcinoma. Tumor smaller than 3 cm were
treated with a single electrode and those greater than 3
cm in diameter required multiple insertions. The
authors proposed that RF ablation is an effective treat-
ment for tumor less than 4 cm in diameter that are not
in close proximity to major blood vessels. Shimizu et al.
[39] reported nine recurrent pelvic lesions in 8 patients
after curative resection of rectal cancer were treated
with real-time magnetic resonance-guided microwave
coagulation therapy (MCT). Local re-recurrence in the
ablated lesion was observed in 2 of 9 lesions. The 3-year
overall survival rate was 12.5% (1/8 patients). Compared
with other interventional procedures, advantages include
interference-free and accurately predictable energy dis-
tribution, treatable size of a target lesion, and lower rate
of acute adverse effects due to maintenance of tissue
continuity. Extensive experience with this technique had
been collected in several preceding studies targeting
pancreatic malignancies as well as one study targeting
lung malignancies [8,40,41]. However, there are few
reports on CT guided implantation of radioactive seeds
Figure 2 Locally recurrent rectal cancer with
125I seeds implant under CT guidance. (a) CT scan shows that
125I seeds are implanted into
the tumor via 18G implantation needles (arrow). (b) CT scan shows the distribution of
125I seeds post implantation (arrow). (c) 2 month follow-
up. CT scan shows recurrent tumor partially decreased and
125I seeds gathered together (arrow).
Figure 3 Local control curve after CT-guided
125I implantation.
Figure 4 Overall survival curve after CT-guided
125I
implantation.
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our institution, the most commonly used isotope is
125I,
and
125I placement has become a routine treatment for
recurrent tumors at various sites. Therefore, we here
present the results of 20 local recurrent rectal carcinoma
patients following
125I seeds implantation.
Possible advantages of
125I seeds over other forms of
radiotherapy are as follows: 1. Radiation from seeds is
characterized by attenuation over a short distance, which
can keep a higher accumulative dose (up to 160 Gy)
within the tumor. 2.
125I seeds can kill tumor cells conti-
nually by keeping cells in the resting period and causing
tumor stem cell apoptosis. 3. Deficiency of oxygen is a
bottleneck of conventional external radiotherapy.
Does et al. first reported 30 local recurrent rectal can-
cer patients treated with brachytherapy [43]. Mean fol-
low-up and local control for gross residual disease and
microscopic residual disease were 26.5 months and 37.5
percent versus 34 months and 66 percent. Eighteen
patients (64%) had local recurrent rectal cancer under
control in his series. Martinez et al. reported a similar
experience in 29 patients with colorectal adenocarci-
noma recurrent in the pelvis treated with permanent
125I seed implantation [44]. All patients had undergone
prior surgery, and 72% of them had prior EBRT. The
implanted residual tumor volume was microscopic in
38% and gross in 62%. The implanted area received a
median minimal peripheral dose of 140 Gy to total
decay. The 1-year, 2-year, and 4-year actuarial locoregio-
nal control rates were 38%, 17%, and 17%, respectively,
w i t ham e d i a nt i m et ol o c a lf a i l u r eo f1 1m o n t h s .T h e
median overall survival rate was 18 month.
Compared to intraoperative brachytherapy, the percu-
taneous implantation of
125I seeds used in our series may
have certain advantages, such as better placement of
seeds using image guidance and more precise seed distri-
bution in target volume. In our group of patients we
implanted
125I seeds under CT guidance and repeated
CT after implantation which showed even distribution of
radioactive seeds. Overall response rate of 75%, local con-
trol rate of 90%, and pain relief rate of 85% demonstrated
promising clinical outcomes in this group. Follow-up
period was 2 to 34 months. Median survival time for all
patients was 18.8 months (95% CI: 3.5-22.4 months). The
estimated 1- and 2-year survival rates were 75% and 25%,
respectively. These data suggest that
125I seed implanta-
tion under CT guidance has the potential to improve
local control of recurrent rectal cancer.
Koutrouvelis reported a case of CT-guided salvage bra-
chytherapy of recurrent colorectal cancer in the pelvis [45]
in a patient whose initial CEA was 67.0 ng/mL. After suc-
cessful Iodine-125 seed implantation the CEA level
dropped to 5.7 ng/mL 12 months later. In our series, nine
patients had elevated serum CEA level before
implantation. 1-3 months following implantation, the CEA
was reduced in 5 patients, unchanged in three and
increased in one. Thus, monitoring of sequential serum
CEA levels pre- and post-implantation with local recurrent
rectal cancer might help evaluate treatment responses.
Finally, there were fewer complications compared with
other interventional ablation procedures. From these
data, it appeared that
125I seed implantation of recurrent
rectal tumors offered both control of the primary tumor
and significant palliation of symptoms.
In conclusion, this study suggests that CT-guided bra-
chytherapy using
125I seeds implantation is safe, useful
and uncomplicated and could produce significant pain
relief for treating local recurrent rectal carcinoma. The
long-term effectiveness of this treatment modality is still
under investigation.
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